1227068-53-2

Basic information

• Product Name: 4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)aniline
• Synonyms: 4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)aniline
• CAS NO: 1227068-53-2
• Molecular Weight: 271.319
• Mol File: 1227068-53-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)aniline(1227068-53-2)
• EPA Substance Registry System: 4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)aniline(1227068-53-2)

Safety Data

• Hazardous Substances Data: 1227068-53-2(Hazardous Substances Data)

Upstream product

• 1227068-52-1 2-fluoro-3-(tetrahydro-2H-pyran-4-yl)pyrazine 
• 123-30-8 4-amino-phenol 
• 25637-16-5 4-bromotetrahydro-2H-pyran 
• 105130-25-4 4-(3-chloropyrazin-2-yloxy)benzenamine 
• 1231926-02-5 4-(3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yloxy)aniline 

Downstream Products

• 1227067-42-6 N-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)phenyl)-1H-benzo[d]imidazol-2-amine 
• 1227067-46-0 7-methoxy-N-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)phenyl)-1H-benzo[d]imidazol-2-amine 
• 1231923-68-4 N-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)phenyl)-5-(trifluoromethyl)pyridin-2-amine 
• 1231923-67-3 5-methyl-N-(4-(3-(tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)phenyl)pyridin-2-amine 

Relevant articles and documents

AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, X5, X6, X7, X8, and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2, and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R2, R3, R4, R5, R6, R7, R9, X1, X2, and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.